Dr. Ramalingam Explores Cytotoxics in Lung Cancer

Suresh S. Ramalingam, MD
Published: Tuesday, Jan 22, 2013

Suresh S. Ramalingam, MD, chief of Thoracic Oncology and director of Medical Oncology at Emory University’s Winship Cancer Institute, explains that a number of new cytotoxic drugs are being developed in combination with targeted therapies, such as EGFR inhibitors.

The microtubule inhibitor eribulin mesylate (Halaven) is being examined in combination with the EGFR inhibitor erlotinib in patients with advanced non-small cell lung cancer (NSCLC). Eribulin has shown activity in NSCLC patients and is already approved in metastatic breast cancer leading to the rationale to explore it further in NSCLC.

Ramalingam believes the appeal of investigating newer cytotoxic agents, such as eribulin, is based on how readily these agents work in combination with existing cytotoxics and targeted therapies.

Suresh S. Ramalingam, MD, chief of Thoracic Oncology and director of Medical Oncology at Emory University’s Winship Cancer Institute, explains that a number of new cytotoxic drugs are being developed in combination with targeted therapies, such as EGFR inhibitors.

The microtubule inhibitor eribulin mesylate (Halaven) is being examined in combination with the EGFR inhibitor erlotinib in patients with advanced non-small cell lung cancer (NSCLC). Eribulin has shown activity in NSCLC patients and is already approved in metastatic breast cancer leading to the rationale to explore it further in NSCLC.

Ramalingam believes the appeal of investigating newer cytotoxic agents, such as eribulin, is based on how readily these agents work in combination with existing cytotoxics and targeted therapies.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x